Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 4/20 | 1.00 |
| ▸ | ZAP70 | P43403 | 6/20 | 0.71 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.70 |
| ▸ | EGFR | P00533 | 4/20 | 0.70 |
| ▸ | IGF1R | P08069 | 3/20 | 0.70 |
| ▸ | GSK3A | P49840 | 2/20 | 0.70 |
| ▸ | CDC7 | O00311 | 2/20 | 0.70 |
| ▸ | PLK4 | O00444 | 2/20 | 0.70 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.70 |
| ▸ | AURKA | O14965 | 2/20 | 0.70 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.70 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.70 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.70 |
| ▸ | JAK2 | O60674 | 2/20 | 0.70 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.70 |
| ▸ | PAK4 | O96013 | 2/20 | 0.70 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.70 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.70 |
| ▸ | PRKCG | P05129 | 2/20 | 0.70 |
| ▸ | LCK | P06239 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29900883 | 1.00 | ULK1 (1.00) | ULK1ZAP70ALKEGFRIGF1R | |
| SCHEMBL380944 | 0.94 | ULK1 (0.88) | ULK1ZAP70ALKEGFRIGF1R | |
| SCHEMBL12781486 | 0.92 | ULK1 (0.85) | ULK1ZAP70ALKEGFRIGF1R | |
| SCHEMBL12892788 | 0.92 | ULK1 (0.84) | ULK1ZAP70ALKEGFRIGF1R | |
| SCHEMBL12780549 | 0.92 | ULK1 (0.84) | ULK1ZAP70ALKEGFRIGF1R | |
| SCHEMBL282266 | 0.91 | ULK1 (0.84) | ULK1ZAP70ALKEGFRIGF1R | |
| SCHEMBL12780145 | 0.91 | ZAP70 (0.85) | ULK1ZAP70ALKEGFRIGF1R | |
| SCHEMBL12892784 | 0.91 | ULK1 (0.83) | ULK1ZAP70ALKEGFRIGF1R | |
| SCHEMBL375362 | 0.91 | ULK1 (0.83) | ULK1ZAP70ALKEGFRIGF1R | |
| SCHEMBL12892894 | 0.91 | ULK1 (0.83) | ULK1ZAP70ALKEGFRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130766-A1 | MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2023-04-27 | — | — | US | disclosed |
| US-20230130766-A1 | MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2023-04-27 | — | — | US | disclosed |
| EP-4070795-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | Salk Institute for Biological Studies (US) | 2022-10-12 | — | — | EP | disclosed |
| EP-3185868-B1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INST FOR BIOLOGICAL STUDI (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2021163633-A1 | MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2021-08-19 | — | — | WO | disclosed |
| US-10774092-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774092-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-09-15 | — | — | US | disclosed |
| US-10689397-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-06-23 | — | — | US | disclosed |
| US-10689397-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-06-23 | — | — | US | disclosed |
| US-20200046700-A1 | FOCAL ADHESION KINASE INHIBITOR AS A THERAPEUTIC AGENT IN DIABETES | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-02-13 | — | — | US | disclosed |
| US-7893074-B2 | inhibition of focal adhesion kinase or/and IGF-1 Receptor; for example: 2-[2-(2,5-Dimethoxy-phenylamino)-5-nitro-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide | NOVARTIS AG (CH) | 2011-02-22 | — | — | US | disclosed |
| EP-1606265-B1 | 2, 4- DI (PHENYLAMINO) PYRIMIDINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2011-02-02 | — | — | EP | disclosed |
| EP-2275413-A1 | 2,4-di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders. | Novartis AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
| US-20060247241-A1 | 2,4-Di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | NOVARTIS AG (CH) | 2006-11-02 | — | — | US | disclosed |
| EP-1660458-A1 | 2, 4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | Novartis AG (CH) | 2006-05-31 | — | — | EP | disclosed |
| EP-1606265-A1 | 2, 4- DI (PHENYLAMINO) PYRIMIDINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | Novartis AG (CH) | 2005-12-21 | — | — | EP | disclosed |
| WO-2005016894-A1 | 2, 4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2005-02-24 | — | — | WO | disclosed |
| WO-2004080980-A1 | 2, 4- DI (PHENYLAMINO) PYRIMIDINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689397-B2 | ULK1 inhibitors and methods using same | ULK1, ULK2, ULK3 | ULK1 1/4885ZAP70 695/4885ALK 3428/4885 |
| US-20200046700-A1 | FOCAL ADHESION KINASE INHIBITOR AS A THERAPEUTIC AGENT IN DIABETES | PTK2, CTTN, IAPP | ULK1 1212/4885ZAP70 554/4885ALK 3826/4885 |
| US-20230130766-A1 | MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS | ULK1, ULK2, ULK3 | ULK1 1/4885ZAP70 691/4885ALK 2565/4885 |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | TYMS, TYMP, DPYD | ULK1 2458/4885ZAP70 302/4885ALK 3200/4885 |
| US-10774092-B2 | ULK1 inhibitors and methods using same | ULK1, ULK2, ULK3 | ULK1 1/4885ZAP70 695/4885ALK 3428/4885 |
| US-20060247241-A1 | 2,4-Di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | TYMS, UMPS, TYMP | ULK1 2014/4885ZAP70 219/4885ALK 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.